Skip to main content

SUMMIT MAX Clinical Trial

The FIRST and ONLY multicenter, randomized controlled trial for aspiration thrombectomy, using the HiPoint® 88/70 Reperfusion Catheter and the Tenzing® 8/7 Delivery Catheter featuring the Monopoint® Approach.

Rail-based HiPoint Reperfusion Catheter is the FIRST and ONLY 0.088″ super-bore catheter to receive FDA clearance for direct aspiration of clot in stroke patients.

NCT05018650

Study Objective: To evaluate the safety and effectiveness of the HiPoint 88/70 Reperfusion System.

Efficient, Effective Intervention

96% successful delivery of HiPoint to the M1* Powered by Tenzing Delivery
68% First Pass Effect mTICI≥2c*
84% First Pass Effect mTICI≥2b* Highest recorded First Pass Effect (in Stroke RCTs)
0% incidence of sICH* Excellent safety profile
96% of the time no adjunctive devices required* Streamlined setup with reduced stent retriever use
*Data from top 3 enrolling SUMMIT MAX sites

Route 92 Medical is the first company to complete enrollment in a randomized controlled trial studying the safety and efficacy of a “super-bore” aspiration catheter with at least an 0.088” inner diameter for the treatment of a large vessel occlusion, the cause of many acute ischemic strokes.

Learn more about the HiPoint Reperfusion System→